The Future of Cannabis Stocks in 2021
When is the right time to buy stock in the cannabis market? The time is now!
Staff or Guest writer for The Dog of Wall Street.
2021-01-09 17:22

In 2018, the legal cannabis sector had an estimated $64.3 billion worth and is expected to grow by $29.7 billion in the next four years. As research develops on the benefits of cannabis, so does the popularity and accessibility thereof, which drives sales.

Cresco Labs (OTC: CRLBF) and Curaleaf (OTC: CURLF) saw an increase in their quarterly revenue in 2020, and they are not slowing down. This increase is because States across the country are legalizing the use of medical marijuana and decriminalizing it. Last month, the House voted on the MORE Act (Marijuana Opportunity Reinvestment and Expungement) with a 228-164 win to take cannabis off the federally controlled substances list. The bill hasn't passed the Senate, however with a Biden Administration and a Democratic majority on the Senate, it offers tailwinds for 2021.

So, when should you buy cannabis stocks? This is the year to be buying cannabis stock if you haven’t already done so. With the increase in demand for all forms of marijuana, stock prices will see hikes.

Aurora Cannabis

Aurora Cannabis (NYSE: ACB), a Canadian stock that saw many lows in previous years, will have an opportunity to see wins if they’re able to rescale production and develop various products. They experienced a tough year in 2020, with operations scaled back and multiple staff layoffs. Aurora was also in the trenches when they almost got removed from the New York Stock Exchange earlier in the year. Aurora has the potential to drive sales, but it will be a long process if management can get their act together and run their operations more tenaciously.


Tilray (NASDAQ: TLRY) started the year on a high, with nearly 9% in gains. This Canadian company can become more bullish, but for now, they have to wait for marijuana to legalize at a federal level, and exports will be allowed. Another positive for this pot stock is the merge between them and Aphria (NASDAQ: APHA), which makes them the largest cannabis company worldwide. This merger will allow them to be one of the biggest competitors in the cannabis market once federal law changes. Tilray will be a good investment in the long term, but it’s best to wait it out for a while to see how the merger affects the company after the transaction has been completed.

What’s Next in 2021

We can only hope that laws will change sooner rather than later, and Canadian cannabis companies can begin to export their products into the US legally. Until then, believers in cannabis stock should keep the faith, as 2021 can prove to be a momentous year for them.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2021-01-09 17:22

About the Author
Staff or Guest writer for The Dog of Wall Street.

Analyst Ratings
Target Price $9.98
# of Analysts 3
Last updated 2021-09-20

Canopy Growth Leads the Way
Canopy’s stock is already up over 18% since the start of the year, and has recovered nicely since the sudden bear market in March of 2020 when it hit single digit prices.
By Mike Sakuraba | 9 months ago

Aurora Cannabis Inc. (ACB) reports its financial results for the first quarter, shares rise
Aurora Cannabis first-quarter revenue beat estimates, sending its shares up more than 30 in the pre-market trading Monday
By Staff | 11 months ago

Can Aurora Cannabis Ever Return to Glory?
While Aurora is still standing on its own two feet, the Canadian company will need to produce some positive earnings news or another rough quarter could lie ahead.
By Mike Sakuraba | 1 year ago

2 Stocks You Need to Upgrade Now
Let’s take a look at a couple companies that recently took another step in their growth stories.
By Mike Sakuraba | 1 day ago

Tesla's Forecast for 2022
The electric vehicle sector has been busy as of late, but not much in terms of news from Tesla.
By Mike Sakuraba | 5 days ago

Better Investment: Pfizer or Moderna
This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.
By Mike Sakuraba | 1 week ago